|
SMU1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.09400000017857E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.86739999999963E-05 |
| Normal-vs-Stage2 |
4.181400E-03 |
| Normal-vs-Stage3 |
6.19809999991006E-07 |
| Normal-vs-Stage4 |
1.10839999956092E-07 |
| Stage1-vs-Stage2 |
8.232600E-01 |
| Stage1-vs-Stage3 |
1.732350E-01 |
| Stage1-vs-Stage4 |
2.241600E-02 |
| Stage2-vs-Stage3 |
2.813800E-01 |
| Stage2-vs-Stage4 |
1.078820E-01 |
| Stage3-vs-Stage4 |
3.993400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.2617000002051E-07 |
| Normal-vs-AfricanAmerican |
1.244390E-01 |
| Normal-vs-Asian |
3.411100E-04 |
| Caucasian-vs-AfricanAmerican |
1.211370E-01 |
| Caucasian-vs-Asian |
8.643600E-01 |
| AfricanAmerican-vs-Asian |
2.217600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.28119999954058E-07 |
| Normal-vs-Female |
3.46350000002271E-06 |
| Male-vs-Female |
2.314200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.33190000000261E-05 |
| Normal-vs-Age(41-60Yrs) |
3.99650000004748E-06 |
| Normal-vs-Age(61-80Yrs) |
6.44430000029672E-07 |
| Normal-vs-Age(81-100Yrs) |
3.692400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.741800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.535170E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.138000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.175400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.410400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.705600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.410300E-02 |
| Classical-VS-Follicular |
3.243600E-02 |
| Classical-VS-Other |
6.474200E-02 |
| Classical-VS-Normal |
9.86689999999957E-05 |
| Tall-VS-Follicular |
8.011000E-01 |
| Tall-VS-Other |
3.182200E-01 |
| Tall-VS-Normal |
4.57399999997943E-06 |
| Follicular-VS-Other |
3.832600E-01 |
| Follicular-VS-Normal |
1.60967999999206E-05 |
| Other-VS-Normal |
2.595400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.12489999998444E-06 |
| Normal-vs-N1 |
1.33979999983325E-07 |
| N0-vs-N1 |
6.655900E-02 |
|
|
